A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced solid tumors.

被引：9
|
作者：
LoRusso, Patricia
Gounder, Mrinal M.
Patel, Manish R.
Yamamoto, Noboru
Bauer, Todd Michael
Laurie, Scott
Grempler, Rolf
Davenport, Teffany
Geng, Junxian
Rohrbacher, Maren
Lahmar, Mehdi
机构：
[1] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Florida Canc Specialists & Res Inst, Sarah Cannon Res Inst, Sarasota, FL USA
[4] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan
[5] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[6] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada
[7] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[8] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[9] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.3016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3016
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors.
    Zhou, Qing
    Yang, Nong
    Zhao, Jun
    Dong, Xiaorong
    Wang, Huijuan
    Yuan, Ying
    Yu, Yan
    Zhang, Meijiang
    Zhang, Sujie
    Huang, Mengna
    Shen, Yuping
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [42] A phase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors.
    Kurzrock, Razelle
    Blay, Jean-Yves
    Binh Bui Nguyen
    Wagner, Andrew J.
    Maki, Robert G.
    Schwartz, Gary K.
    Patnaik, Amita
    Gore, Lia
    Wu, Lin
    Vassilev, Lyubomir T.
    Ding, Michelle
    Geho, David
    Zhi, Jianguo
    Middleton, Steven
    Nichols, Gwen L.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.
    Rasco, Drew W.
    Lakhani, Nehal J.
    Li, Yufeng
    Men, Lichuang
    Wang, Hengbang
    Ji, Jiao
    Tang, Yuefen
    Liang, Zhiyan
    Amaya, Alex
    Estkowski, Kathy
    Sun, Joan
    Huang, Yingjie
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [44] Sunitinib (SU) plus docetaxel (D) in patients (pts) with advanced solid tumors: a phase I dose-escalation and pharmacokinetic (PK) study
    Traynor, A.
    Sandler, A.
    Schiller, J. H.
    Ilagan, J.
    Harper, K.
    VerMeulen, W.
    Liu, G.
    Tye, L.
    Chao, R.
    Robert, F.
    EJC SUPPLEMENTS, 2007, 5 (04): : 110 - 110
  • [45] A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors
    de Braud, F.
    Cascinu, S.
    Spitaleri, G.
    Pilz, K.
    Clementi, L.
    Liu, D.
    Sikken, P.
    De Pas, T.
    ANNALS OF ONCOLOGY, 2015, 26 (11) : 2341 - 2346
  • [46] Phase I dose-escalation study of brostallicin in combination with cisplatin (cDDP) in patients with advanced solid tumors
    Lorusso, D.
    Fornari, G.
    Caponigro, F.
    Quirino, M.
    Merlano, M.
    Airoldi, M.
    Schena, M.
    Jannuzzo, M. G.
    Crippa, S.
    Scambia, G.
    EJC SUPPLEMENTS, 2007, 5 (04): : 111 - 112
  • [47] Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors
    A. Craig Lockhart
    Shankar Sundaram
    John Sarantopoulos
    Monica M. Mita
    Andrea Wang-Gillam
    Jennifer L. Moseley
    Stephanie L. Barber
    Alex R. Lane
    Claudine Wack
    Laurent Kassalow
    Jean-François Dedieu
    Alain C. Mita
    Investigational New Drugs, 2014, 32 : 1236 - 1245
  • [48] Phase I dose-escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors
    Doz, Francois
    Locatelli, Franco
    Baruchel, Andre
    Blin, Nicolas
    De Moerloose, Barbara
    Frappaz, Didier
    Dworzak, Michael
    Fischer, Matthias
    Stary, Jan
    Fuertig, Rene
    Riemann, Kathrin
    Taube, Tillmann
    Reinhardt, Dirk
    PEDIATRIC BLOOD & CANCER, 2019, 66 (10)
  • [49] A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors
    Jeffrey R. Infante
    Roger B. Cohen
    Kevin B. Kim
    Howard A. Burris
    Gregory Curt
    Ugochi Emeribe
    Delyth Clemett
    Helen K. Tomkinson
    Patricia M. LoRusso
    Investigational New Drugs, 2017, 35 : 576 - 588
  • [50] Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors
    Lockhart, A. Craig
    Sundaram, Shankar
    Sarantopoulos, John
    Mita, Monica M.
    Wang-Gillam, Andrea
    Moseley, Jennifer L.
    Barber, Stephanie L.
    Lane, Alex R.
    Wack, Claudine
    Kassalow, Laurent
    Dedieu, Jean-Francois
    Mita, Alain C.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) : 1236 - 1245
12345